BTAI - BioXcel Therapeutics, Inc.
| Previous Close | 9.63 |
| Open | 9.77 |
| Bid | 9.66 x 800 |
| Ask | 9.92 x 800 |
| Day's Range | 9.72 - 9.98 |
| 52 Week Range | 2.41 - 14.79 |
| Volume | 16,891 |
| Avg. Volume | 60,720 |
| Market Cap | 153.368M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.32 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.20 |
- GlobeNewswire•15 days ago
BioXcel Therapeutics to Present at Upcoming Investor Conferences in April
NEW HAVEN, Conn., April 03, 2019 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that the Company will deliver corporate overview presentations at both.
- GlobeNewswire•17 days ago
BioXcel Therapeutics Showcases Data on BXCL701 in Combination with OX40 Agonist in Late-breaking Poster Presentation at AACR Annual Meeting
Novel combination achieves synergistic anti-tumor effect and survival benefit Demonstrates BXCL701’s potential ability to bridge innate and adaptive immune systems Clinical.
- GlobeNewswire•24 days ago
BioXcel Therapeutics Files Clinical Trial Application for the Development of BXCL701 and Pembrolizumab in Neuroendocrine Prostate Cancer (tNEPC)
BioXcel Therapeutics, Inc. (“BTI”) (BTAI) today announced that it has filed a Clinical Trial Application (CTA) with the U.K. health authorities for its lead immuno-oncology asset, BXCL701, an orally-available small molecule immune-modulator with dual mechanisms of action, in combination with pembrolizumab (Keytruda®), a checkpoint inhibitor, in tNEPC. BTI is a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology.
- GlobeNewswire•last month
BioXcel Therapeutics to Present at 29th Annual Oppenheimer Healthcare Conference
NEW HAVEN, Conn., March 13, 2019 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will.
- GlobeNewswire•last month
BioXcel Therapeutics Announces Late Breaking Data Presentation at AACR 2019 Annual Meeting
BioXcel Therapeutics, Inc. (“BTI”) (BTAI) today announced that it will present a late breaking poster featuring data from a preclinical study of the Company’s BXCL701 and an OX40-agonist antibody as a potential combination therapy for treatment of certain solid tumors at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019 being held from March 29 to April 3, 2019 in Atlanta, Georgia. Dr. Vince O’Neill, Chief Medical Officer of BTI commented, “The encouraging results from this preclinical study of BXCL701 and an OX40 agonist, an investigational monoclonal antibody immunotherapy, represent a potentially valuable therapeutic option for cancer patients.
- GlobeNewswire•last month
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2018 Quarterly Results and Provides Business Update
BXCL501 Pharmacokinetic (Bioavailability) and safety study on track to read out in second quarter 2019; initiation of Phase 2/3 Registration Trial expected in second half 2019.
- GlobeNewswire•last month
BioXcel Therapeutics to Participate in Upcoming Investor Conferences in March
NEW HAVEN, Conn., March 05, 2019 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will.
- GlobeNewswire•last month
BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer
Clinical partnership to evaluate triple combination of BioXcel Therapeutics’ BXCL701, Nektar’s NKTR-214 and avelumab (Merck KGaA, Darmstadt, Germany and Pfizer) in pancreatic.
- GlobeNewswire•2 months ago
BioXcel Therapeutics to Host Fourth Quarter & Full Year 2018 Financial Results and Business Update Conference Call
NEW HAVEN, Conn., March 01, 2019 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial.
- GlobeNewswire•2 months ago
BioXcel Therapeutics to Present at 2019 BIO CEO & Investor Conference
NEW HAVEN, Conn., Feb. 06, 2019 -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Chief Executive Officer of BTI, will.
- GlobeNewswire•2 months ago
BioXcel Therapeutics Expands Indication for Lead Neuroscience Asset, BXCL501, to Treat Symptoms Associated with Opioid Drug Withdrawal
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), today announced proof-of-concept data from its Phase 1b study of intravenously-administered dexmedetomidine (IV Dex) in patients suffering from opioid withdrawal symptoms. The positive data from this Phase 1b trial provides evidence to expand the potential market for BXCL501, a first in class proprietary sublingual film of Dex, beyond its current focus for acute treatment of agitation in neuropsychiatric indications.
- ACCESSWIRE•3 months ago
The Most Innovative Healthcare AI Developments of 2019
HOUSTON, TX / ACCESSWIRE / January 9, 2019 / Technology has changed in the blink of an eye. Concepts that were nothing more than science fiction, such as artificial intelligence (AI) and machine learning are now quickly disrupting global industries with significant capabilities. In fact, the limitless potential of AI alone is disrupting businesses, the way we conduct our affairs, and even the way financial institutions conduct high-frequency trading.
- GlobeNewswire•3 months ago
BioXcel Therapeutics Reports Positive Human Proof-of-Concept Data for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
Primary endpoint (safety and tolerability) met, with clinical benefit observed in 7 of 10 patients Proof-of-Concept established in agitated patients across multiple.
- Zacks•4 months ago
BioXcel Surges on Fast Track Designation to Agitation Drug
BioXcel (BTAI) soars after the FDA granted Fast Track designation to its lead candidate, BXCL501.
- ACCESSWIRE•4 months ago
These 4 Healthcare Stocks Are Gaining Speed
CORAL GABLES, FL / ACCESSWIRE / December 27, 2018 / With the new year less than one week away, the healthcare industry is effervescent with excitement as companies work towards designing new methods and technologies to dramatically improve care options available to consumers. Premier Health Group (OTC:PHGRF) (CSE:PHGI), BioXcel Therapeutics Inc (BTAI), Axsome Therapeutics Inc (AXSM), and Adial Pharmaceuticals are 4 healthcare stocks representing companies dead-set on fostering the best possible care options and products in their sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company you may not have heard of, but may want to look into as they break new ground on inventive approaches to products and treatments previously determined to be unchangeable.
- GlobeNewswire•4 months ago
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), today announced that the U.S. FDA has granted Fast Track Designation for its investigational drug BXCL501, a proprietary sublingual film of dexmedetomidine, for the treatment of acute agitation. BTI is a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology.
- GlobeNewswire•4 months ago
BioXcel Therapeutics Doses First Subjects in Pharmacokinetic (Bioavailability) and Safety Study of BXCL501 for the Acute Treatment of Agitation
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), today announced that the first six subjects have been dosed in the Company’s Phase 1 pharmacokinetic (bioavailability) and safety study of BXCL501, a proprietary sublingual thin-film formulation of dexmedetomidine (Dex). BTI is a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology. The IND-opening Phase 1 study is a placebo-controlled, single dose, dose-escalation study of BXCL501 that is expected to enroll up to 60 healthy adult volunteers across various dosing groups.
- Benzinga•4 months ago
The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 11) Imprimis Pharmaceuticals Inc (NASDAQ: IMMY ) OvaScience ...
- GlobeNewswire•4 months ago
BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Neuroscience Candidate, BXCL501 for the Acute Treatment of Agitation
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), today announced that the U.S. Food and Drug Administration (“FDA”), has accepted its Investigational New Drug (IND) application for lead neuroscience candidate, BXCL501. BTI plans to evaluate BXCL501, a proprietary sublingual thin-film formulation of dexmedetomidine (Dex) in a first-in-human pharmacokinetic (bioavailability) and safety study in healthy volunteers.
- GlobeNewswire•4 months ago
BioXcel Therapeutics to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
NEW HAVEN, Conn., Dec. 03, 2018 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial.
- GlobeNewswire•5 months ago
Market Trends Toward New Normal in Transcat, BioXcel Therapeutics, Youngevity International, Aquestive Therapeutics, TORM, and Transglobe Energy — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•5 months ago
BioXcel Therapeutics Reports Positive Results from Study in Agitated Schizophrenia Patients Supporting BXCL501 Clinical Development
BioXcel Therapeutics, Inc. (“BTI”) (BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced positive results from a Phase 1b study evaluating intravenously (IV) administered dexmedetomidine (Dex) for acute treatment of agitation in patients suffering from schizophrenia. The trial met its primary endpoint by identifying a safe dose of IV Dex that produced a mild arousable sedation, defined by a RASS1 (Richmond Agitation Sedation Scale) score of -1.
- GlobeNewswire•5 months ago
BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update
NEW HAVEN, Conn., Nov. 09, 2018 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial.
- GlobeNewswire•5 months ago
BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), today announced that the U.S. Food and Drug Administration (“FDA”), has accepted its Investigational New Drug (“IND”) application for its lead immuno-oncology candidate, BXCL701. BTI plans to evaluate BXCL701 in combination with pembrolizumab (Keytruda®) as a potential therapy for treatment-emergent neuroendocrine prostate cancer (“tNEPC”), with the trial expected to initiate in the fourth quarter of 2018.
- GlobeNewswire•5 months ago
BioXcel Therapeutics to Host Third Quarter 2018 Financial Results and Business Update Conference Call
Conference call scheduled for November 09, 2018 at 8:00 AM ET NEW HAVEN, Conn., Nov. 02, 2018 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage.
